Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 August 2019 | Story Eugene Seegers
Simonè Nel (Read More)
“When looking at the simply amazing female leadership emerging at the UFS — academic as well as administrative — I see hope and growth,” says Simoné Nel, a member of the management team on the South Campus.

Simoné Nel heads up the Support Services division on the UFS South Campus. Despite challenges during her youth, she learnt the power of strong examples to look up to, and still lives by the mantra she learnt in primary school from her Drum Majorettes coach. She believes that inspiration can come from mundane sources, day-to-day conversations, or even her children; she is the mother of a 10-year-old son and a 7-year-old daughter. In fact, her best example of teamwork comes from her experiences as mother: “Just watch what happens when a mother is calling frantically for her child if he slips from her grip; EVERYONE helps to find him!”

Tell us about your childhood: What are some of the lessons you learned early on? 

Growing up in the Western Cape, I had a primary school teacher and coach who taught me the value of the saying: “It is not the hours you put in, but what you put into the hours.” I still live by this; trying to make the most of every hour. Both of my parents passed away at a fairly young age, which made this just so much more true. USE your given time and LIVE as much as possible! Take joy in as many experiences as possible – even if it is a seemingly negative experience.

What inspires you?

Intelligent conversations, great music, my daughter’s energy, family time, and compassion in action. Simoné says her definition of compassion in action is: People like the rest of us with full-time jobs, dedicating every little spare time to helping women/children/families in need or distress; friends involved with finding forever homes for abandoned pets; the regular guy in the street helping a child stand up after falling from the curb.

How do you envision the UFS of the future — especially with regard to women's issues? 

When looking at the simply amazing female leadership emerging at the UFS – academic as well as administrative — I see hope and growth. Just page through the latest issue of Dumela or browse our UFS website: These are strong women; not afraid of embracing who they are and with a need to rise up. I am part of an all-girls team at the South Campus (coincidentally!) and we support each other in every possible way. Whether I know them as Prof, Doc, Ma’am, Mom, Sister, Vriendin – they are all Wonder Women to me.

Tell us something no-one (or only a few people) know about you?

I am in love with (a very broad scope of) music, from Beethoven on full volume to some serious rock. Yes, I sing along to my heart’s content. I am also from Scottish decent and admire my cousins in full costume (kilt and all!).

What does ‘success’ mean to you?

My definition of success has certainly taken a 180-degree turn. When I was still a young student, I longed for academic success and to pursue my PhD studies as soon as possible. Now I am a mom and wife — first and foremost — and still working on my master’s degree. At the end of a fruitful day at the office, a glass of wine with my husband, and hugs, kisses, and laughs from my children, I’d say I had a most successful day.

What ‘words of wisdom’ do you always fall back on? 

I learnt this early on, but had it confirmed in JRR Tolkien’s The Fellowship of the Ring: There is always HOPE.

Lastly, my mom taught me this gem: ‘A little kindness goes a long way.’

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept